Reymann A, Bunge A, Läer S, Dietel M
Abteilung Allgemeine Pharmakologie, Universität Hamburg, Germany.
Pharmazie. 1996 Mar;51(3):171-6.
Manifold mechanisms of resistance can be expressed by malignancies. Profound information on this aspect is a prerequisite for comprehensive individual chemotherapy. Based on both morphological and functional findings, the diagnosis of P-Glycoprotein (P-Gp) mediated Multidrug Resistance (MDR) can be verified. In order to describe minimum criteria for conclusive diagnosis, morphological and biochemical findings (Immunocytochemistry, RT-PCR, ultrastructural and Laser-Scan microscopy) and functional data (cytostatic drug transport, proliferation) were correlated in tumor cell lines of the MDR phenotype as opposed to cells with atypical resistance. Frequently, single features of MDR are found in atypical, P-Gp negative resistance. Accumulation deficits for mitoxantrone based on vesicular drug transport were found in P-Gp negative gastric carcinoma cell line EPG85-257RNOV. Nocodazole blocked microtubule formation which is essential for vesicle transfer from perinuclear regions to the periphery of the cytosol. Cytochalasin blocked exocytosis of drug containing vesicles. MDR modulators were ineffective. Alternatively, P-Gp mediated drug extrusion and exocytosis of drug containing vesicles may constitute complementary mechanisms of resistance. In gastric carcinoma cells EPG85-257DAU, MDR modulators do increase cytosolic daunorubicin load, but drug binding to nuclear target sites is still inhibited due to drug containment within vesicles. To complicate matters, MDR modulators may be functional even in MDR negative cells, as shown in a panel of melanoma cell lines. Data show that conclusive diagnosis of P-Gp-mediated MDR should be based on more than one experimental approach including immunocytochemistry, a sensitive assay such as RT-PCR and--whenever feasible--a functional test.
恶性肿瘤可表现出多种耐药机制。这方面的深入信息是进行全面个体化化疗的前提。基于形态学和功能学的研究结果,可以证实P-糖蛋白(P-Gp)介导的多药耐药(MDR)的诊断。为了描述确诊的最低标准,将MDR表型肿瘤细胞系的形态学和生化研究结果(免疫细胞化学、逆转录聚合酶链反应、超微结构和激光扫描显微镜检查)及功能数据(细胞抑制药物转运、增殖)与具有非典型耐药性的细胞进行了对比。通常,在非典型的、P-Gp阴性耐药中可发现MDR的单一特征。在P-Gp阴性的胃癌细胞系EPG85-257RNOV中,发现基于囊泡药物转运的米托蒽醌蓄积缺陷。诺考达唑可阻断微管形成,而微管形成对于囊泡从核周区域转运至胞质周边至关重要。细胞松弛素可阻断含药囊泡的胞吐作用。MDR调节剂无效。另外,P-Gp介导的药物外排和含药囊泡的胞吐作用可能构成互补的耐药机制。在胃癌细胞EPG85-257DAU中,MDR调节剂确实可增加胞质柔红霉素负荷,但由于药物被包裹在囊泡内,药物与核靶位点的结合仍受到抑制。更复杂的是,MDR调节剂甚至在MDR阴性细胞中也可能发挥作用,如一组黑色素瘤细胞系所示。数据表明,P-Gp介导的MDR的确证诊断应基于多种实验方法,包括免疫细胞化学、一种灵敏的检测方法如逆转录聚合酶链反应以及在可行时进行功能测试。